INTRODUCTION
e CAPRISA004 trial demonstrated for the rst time that a topical microbicide might protect women against sexually transmitted HIV. 1 Tenofovir gel applied intravaginally before and a er sexual intercourse reduced HIV transmission by 39% in a high-risk population. However, these promising results were not replicated in two follow-up studies, probably because of poor compliance with a regimen that required usage just before and a er exposure. 2 Compliance might improve for a microbicide that requires less frequent application that is not temporally linked to sexual exposure. 3 Knocking down host genes that are needed for viral transmission, viral genes, or both can interfere with viral transmission and replication, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] including the sexual transmission of viruses such as HIV. Because gene knockdown persists for over a week in most non-dividing cells, 5, 16 a microbicide based on RNA interference (RNAi) as its active principle could provide a strategy with a manageable dosing schedule for overcoming problems with compliance. In fact, a previous study of gene knockdown in the genital tract showed protection in mice from intravaginal (IVAG) challenge a week later with a lethal dose of herpes simplex virus type 2. 13, 15 siRNAs directed against CCR5 can e ectively silence gene expression in vitro for 3 weeks and prevent viral replication in primary macrophages when challenge is delayed for 3 weeks. 5 CCR5 is the coreceptor used almost exclusively during HIV or SHIV sexual transmission. 17, 18 Blocking CCR5 by more conventional approaches (antibodies, antagonists, and small molecule inhibitors) inhibits sexual transmission in non-human primates. [19] [20] [21] [22] Accomplishing gene knockdown in HIV-susceptible cells, which are refractory to most transfection techniques that could be used in vivo, has been di cult. 5, 6 Although targeted delivery has become possible in recent years, even in vivo, using fusion proteins, which couple a targeting antibody (Ab) fragment to an RNA binding motif, such as protamine, 12, 23, 24 we developed an alternative approach using RNA aptamers. ese are ideally suited for therapeutic applications like topical microbicides, which require repeated administration, because of economical large-scale synthesis and low immunogenicity. 25, 26 Building on the work of other groups targeting prostate cancer 27, 28 and virusinfected cells, 29 we recently showed that chimeric RNAs, composed of a known CD4 aptamer 30 covalently linked to an siRNA, could transfect all CD4 + cells susceptible to HIV in the genital tract of female humanized mice, and speci cally knockdown
Durable Knockdown and Protection From HIV Transmission in Humanized Mice Treated With Gel-formulated CD4 Aptamer-siRNA Chimeras
Topical application of a cocktail of CD4-AsiCs targeting CCR5, gag and vif inhibited HIV vaginal transmission with a high dose of HIV JR-CSF that uniformly infected all control animals. 14 We termed these RNAs, CD4-aptamer-siRNA chimeras (CD4-AsiCs). In that study, CD4-AsiCs were administered according to a complicated schedule-RNAs targeting CCR5 were administered 1 and 2 days before viral challenge and the CD4-AsiCs targeting viral genes were given 24 hours before and 4 hours a er viral challenge. Although the aptamer alone had some antiviral e ect, presumably by blocking virion binding to the CD4 receptor, we showed that siRNA-mediated gene knockdown was the principal mechanism underlying the protective e ect. 14 RNAs were injected in a liquid solution and mice were kept supine for ~5 minutes to prevent the liquid from immediately leaking out of the genital tract. However, a clinically useful microbicide will need to be formulated in a gel suitable for vaginal retention.
Here, we investigate whether gene knockdown and protection can be achieved using a more practical dosing schedule and RNAs formulated in a gel suitable for clinical use. We used polarized human cervicovaginal explants and immunode cient NOD/SCID/IL2Rγ −/− (NSG) mice, reconstituted with CD34 + cells from human fetal liver and implanted with human fetal thymic gra s (so-called "BLT mice"), 14, [31] [32] [33] [34] to investigate questions important for developing a clinically useful microbicide based on CD4-AsiCs as the active ingredient. How long does gene knockdown last and how durable is protection? Could CD4-AsiCs be formulated in an inert nontoxic gel that would be retained within the genital tract without interfering with gene knockdown or antiviral e cacy? Could just knocking down CCR5 or just viral genes provide protection? Are antiviral RNAs protective when administered only a er exposure? We found durable protection for ~4 days with gel-formulated CD4-AsiCs targeting just CCR5 and partial protection from a delayed challenge or when treatment was only given a er exposure. Optimization of CD4-AsiCs (and/or repeated application) would likely lead to further improvement.
RESULTS

CD4-AsiCs stably knockdown gene expression for 3 weeks in vitro
To assess the durability of gene silencing by CD4-AsiCs, we rst incubated resting CD4 + PBMCs from three donors with 1 µmol/l Cy3-labeled CD4-AsiCs against CCR5, a concentration that we previously found provided ~50% maximal in vitro knockdown 14 ( Figure 1) . AsiC-treated cells were cultured in IL-15 under conditions that minimize cell proliferation but maintain cell viability, and RNA uptake and gene silencing in CD4 + T cells was assessed by ow cytometry over 5 weeks. Uptake and , ***P < 10 −7 , t-test) in Cy3 + cells, compared with mock-treated cells, are shown. Data represent the mean ± SEM of data from five donors in three independent experiments Maximal target CCR5 knockdown was achieved 7 days after treatment and was maintained for 2 weeks. were sacri ced 4, 8, and 14 days a er the last treatment (Figure 2) . Mock-treated control mice, similarly treated twice with phosphate-bu ered saline (PBS), were sacri ced 4 days a er the second dose. CD45 and CCR5 expression in CD4 + cells in the vaginal mucosa were evaluated by ow cytometry of single cell suspensions of collagenase-digested tissue. CCR5 and CD45 were stably knocked down for 2 weeks in CD4 + cells in AsiC-treated mice relative to mock-treated controls. e CD45 CD4-AsiC was more e ective at gene knockdown (mean uorescence intensity reduced to 5-10% of control over 2 weeks) than the CCR5 construct (mean uorescence intensity reduced to 20-35% of baseline). A similar experiment conducted in mice prepared from a di erent donor showed similarly stable gene knockdown (data not shown).
CD4-AsiCs maintain activity when formulated in hydroxyethylcellulose
Because a liquid microbicide is not practical for human use, we next evaluated whether uptake and silencing is maintained when CD4-AsiCs are formulated in a hydroxyethyl cellulose (HEC) gel. HEC is an FDA-approved nonionic, nontoxic, chemically stable, water-soluble polymer that has been used as the universal placebo in all HIV microbicide trials since 2005.
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CD4-AsiCs were highly stable in HEC gel or PBS over 72 hours (Figure 3 ). In the presence of vaginal uid, the AsiCs in HEC did not decay at all, whereas the AsiCs in PBS decayed slightly (only by ~20% over 72 hours). To examine the e ect of the gel on gene knockdown, CCR5 or CD45 CD4-AsiCs, premixed in PBS or HEC, were added twice to polarized human cervicovaginal explants, and single cell suspensions, prepared by collagenase digestion, were analyzed for CCR5 and CD45 expression by ow cytometry 4 days a er the second treatment ( Figure 4 ). CD45 mRNA is alternatively spliced to produce three main isoforms; the CD45 siRNA is speci c for the CD45RA and RB isoforms, but is inactive against the RO isoform. Formulation in HEC did not signi cantly a ect gene silencing. Gene knockdown of CCR5 and the siRNA-sensitive isoforms of CD45 (but not CD45RO) occurred in CD4 + T cells and tissue macrophages, but not in CD8 + T cells, suggesting that cell-speci c targeting was maintained. We next assessed whether gel formulation a ects gene knockdown in the genital tract of humanized female mice. CD4-AsiCs against CCR5 and CD45 (40 pmol each) were administered with or without gel formulation twice (spaced by 24 hours) to the genital tract of humanized mice. Four days later, vaginal tissue was harvested, digested with collagenase, and single cell suspensions were analyzed for target gene expression by ow cytometry ( Figure 5 ). Groups of mice treated with PBS or naked siRNAs (±HEC), served as negative controls. Knockdown of CCR5 and targeted CD45 isoforms was similar in mice treated with CD4-AsiCs in PBS and in HEC gel and was speci c to CD4 + , compared with CD8 + , T cells. Naked siRNAs did not induce gene knockdown in T cells and may have been immunostimulatory, because they upregulated CD45RO in both CD4 + and CD8 + lymphocyte populations. CD4-AsiCs in PBS increased CD45RO expression to a lesser extent, but only in CD8 + cells. Although this upregulation was not observed in other experiments, we cannot rule out a low level of immune stimulation by the CCR5 or CD45 CD4-AsiC.
It should also be noted that the degree of knockdown in CD4 + T cells in this in vivo experiment was less than we observed in our published study 14 or in Figure 2 above or in data not shown. Some batches of humanized mice, depending on the human donor, are especially prone to develop gra versus host disease (GvHD) or a wasting syndrome that has been attributed to their conditioning regimen. Either of these conditions may cause more immune activation and increased immune cell tra cking into and out of mucosal tissues, which might a ect knockdown. is batch of mice had a high incidence of wasting, which might be responsible for the atypically poor gene knockdown in this experiment.
Targeting either HIV-encoded genes or host factors using CD4-AsiCs blocks vaginal transmission of HIV to humanized mice
We previously showed that IVAG application of a cocktail of CD4-AsiCs against CCR5, gag, and vif inhibits HIV transmission to BLT mice. 14 We next tested the relative contribution of targeting host or viral genes to HIV inhibition. Using the same dosing regimen, we administered CCR5 CD4-AsiCs 48 hours and 24 hours before IVAG challenge or gag/vif CD4-AsiCs 24 hours before and 4 hours a er IVAG challenge. Mice treated with the cocktail of host and HIV-speci c AsiCs given at the same times were used as a positive control, and mice treated with PBS served as a negative control (Figure 6 ). All control mice became infected and had detectable blood HIV p24 antigen and plasma RNA within 4 weeks of infection, whereas all mice treated with the cocktail, the CCR5 CD4-AsiC or the gag/ vif CD4-AsiCs showed no evidence of infection.
eir CD4 counts remained normal and none had detectable HIV p24 antigen or RNA in their plasma above background during the 10 weeks of observation. At weeks 5 and 8, the p24 Ag level of mice treated with AsiCs targeting just gag and vif had p24 Ag levels just at the threshold of detection. However, the qRT-PCR assay for HIV gag mRNA, which is a more sensitive test for plasma virus, remained below the threshold of detection over the 10 weeks. We therefore interpret these data as showing that gel-formulated CCR5 CD4-AsiCs translates into protection from delayed HIV challenge. us, in two independent experiments, we pretreated groups of humanized BLT mice IVAG twice with 80 pmol of CCR5 CD4-AsiCs either 7 and 6 days, 5 and 4 days, or 2 and 1 days before vaginal challenge with HIV (Figure 7) . For the delayed challenge groups, the CD4-AsiCs were either dissolved in PBS or in HEC gel. e CD4-AsiC-treated mice were compared with mock control animals, which were treated IVAG with either PBS or HEC gel 2 and 1 days before IVAG challenge with HIV. Mice were observed for 8 weeks following challenge. All mock-treated mice became infected and had detectable p24 antigenemia and greatly reduced CD4 + T cell counts within 4 weeks of exposure. e gel on its own did not reduce viral loads or ameliorate the decline in CD4 T cells. As before (Figure 6 ), mice treated with CCR5 CD4-AsiCs 2 and 1 days before viral challenge were completely protected. However, when HIV exposure was delayed for 4 or 6 days a er the last CD4-AsiC application, protection was incomplete in all groups. e most protected mice were those treated with HEC-formulated CD4-AsiCs and challenged 4 days later. In this group, there was no signi cant di erence in mean p24 Ag level or CD4/CD8 ratio throughout the course of the experiment, compared with the completely protected animals who were challenged without delay, and only one mouse showed signs of infection with a slight increase in p24 antigenemia and a modest decline in CD4/CD8 ratio. All mice in the other delayed challenge groups became infected, but had signi cantly reduced viral burden, as measured by HIV p24 Ag that was 1-1.5 logs less than in PBS-treated controls. Moreover, the rate of CD4 + T cell decline was signi cantly less than in mock-treated controls. ere was no signi cant di erence in transmission sequelae (p24 Ag or CD4/CD8 ratio) depending on whether the challenge was performed 4 or 6 days a er treatment with unformulated CCR5 CD4-AsiCs. Mice treated with HEC-formulated CD4-AsiCs and challenged 6 days later had signi cantly less plasma viremia and a less steep drop in CD4/CD8 ratio than mice treated with unformulated CD4-AsiCs. us, protection from transmission was only partial for delayed challenge, and formulation of CD4-AsiCs in HEC improved protection in both the 4 and 6 days delayed challenge groups.
Inhibition of HIV transmission in mice treated with gag/vif CD4-AsiCs after exposure
A potential clinical application of a topical microbicide is postexposure prophylaxis. We previously showed that siRNAs targeting an HSV-2 gene-administered IVAG a er exposure provided protection from a lethal challenge dose of virus. 15, 17 To determine whether interfering with HIV gene expression a er viral exposure could protect humanized mice from transmission, we challenged groups of BLT mice IVAG with an HIV viral dose that uniformly results in infection and then 4 or 24 hours later administered 80 pmol of gag/vif CD4-siCs IVAG (Figure 8) . Control mice were treated with PBS 4 hours a er HIV or mock viral challenge. All mice were evaluated for plasma p24 antigen and CD4 and CD8 T cell counts. All mock-treated mice became infected and had reduced CD4 + T cell counts. Mice treated a er exposure with gag/vif CD4-AsiCs were partially protected, but protection was better in mice treated at 4 hours versus 24 hours. Although two mice became infected in the 4 hours group, the infected mice had low levels of p24 Ag that were close to background and did not show evidence of reduced CD4 T cell counts. All the mice treated 24 hours a er exposure became infected, but their viral burden was reduced by about 0.5 logs. e rate of CD4/CD8 ratio decline was also signi cantly less rapid than the control mice. us, viraltargeted CD4-AsiCs reduced viral burden, more substantially if administered sooner a er exposure, and even protected some mice completely when administered 4 hours a er exposure.
DISCUSSION
e success of any microbicide requires adequate patient compliance. 1, 3, 13, 35, 36 Establishing durable resistance to infection should eliminate the need for microbicide administration just before a sexual encounter, thereby facilitating adherence. RNAi, which knocks down target genes for as long as three weeks in vitro and in vivo, 5, 16 should provide a means for long-lasting protection. Here, we used the BLT mouse model to show that CD4-AsiCs knockdown gene expression in HIV-susceptible cells in the female genital tract for at least two weeks in vivo. Knockdown was comparable when CD4-AsiCs were formulated in HEC, a water-soluble FDAapproved polymer already used in HIV microbicide trials that promotes retention in the female genital tract. 35 Gel formulation actually improved protection from delayed challenge. us, HEC formulation should be used to evaluate siRNA-based microbicides in future animal studies, as they are currently being used to assess small molecule CCR5 inhibitors.
37
CD4-AsiCs can be formulated in a clinically applicable microbicide gel without loss of cell-type speci city, knockdown activity or e ectiveness. Sterilizing protection from a high dose challenge in BLT mice was uniformly achieved when mice were treated to knockdown CCR5 and HIV gag and vif together or the coreceptor or viral genes individually. Protection by targeting just CCR5 should mean that the same microbicide could be used to protect against all viral clades with minimal risk of viral escape or drug resistance. 5, 6 When challenge was performed around the time of treatment, 13 of 13 evaluable mice resisted becoming infected. ese results are encouraging in a model that results in 100% transmission, especially considering that HIV sexual transmission in humans is very ine cient, requiring hundreds of sexual exposures on average to become infected. 18 Directing knockdown to all CD4 + cells capable of being infected could complement gp160-targeted AsiCs, which are e ective only against cells already infected with the virus. 38 Because the human CCR5 sequence we targeted is well conserved in Rhesus macaques, and preliminary data suggest that the human CD4 aptamer binds to macaque CD4, we are planning to test the CCR5 CD4-AsiCs in non-human primates challenged with SHIV virus, which should help us evaluate the promise of CD4-AsiCs for human microbicide use. 19, 21, 22 When challenge was delayed for 4 days a er AsiC application in HEC gel, all mice, but one, were completely protected. No sterilizing protection occurred with 4 days delayed challenge when RNAs were administered in saline or when challenge was delayed until 6 days a er the treatment was completed. However, both viral load and the decline in CD4 counts were signi cantly reduced in AsiC-treated mice under all these conditions. Why gel formulation improved protection is not clear. Contributing factors might be improved stability, longer
Molecular erapy
interface time, more uniform coverage of the luminal surface or better toleration without in ammation of the epithelial tissue when RNAs are incorporated into a gel. It will be worthwhile to evaluate whether CD4-AsiCs can be incorporated into slow-releasing vaginal rings without compromising activity and function to provide even longer term protection.
e decline in protection a er 1 week was unexpected, given the sustained target gene knockdown. Although we cannot conclusively rule out 39 resistance, a more likely explanation might be recruitment of new CD4 + cells to the genital tract that occurred a er treatment. is may be a special problem in the BLT model. ese mice have a high rate of GvHD and wasting, which has been attributed to the conditioning regimen. ese e ects can vary from batch to batch of BLT mice 31, [40] [41] [42] and were more severe in the mice used in the delayed challenge experiments in Figure 6 . GvHD leads to increased T cell activation and tissue tra cking. As HIV preferentially infects activated T cells, 43 transmission may be enhanced in mice with GvHD. In addition, the durability of gene knockdown is reduced in activated cells because siRNAs are diluted with each cell division. siRNAs may also be more rapidly degraded in activated, than in resting, T cells. All of these considerations suggest that HIV may be more di cult to inhibit in the setting of GvHD. ese factors may also apply to women with ongoing vaginal or systemic infection or other conditions associated with in ammation, who are more susceptible to transmission, [44] [45] [46] and for whom it may be more challenging to achieve durable knockdown.
Post-exposure prophylaxis is possible using antiretroviral drugs. 47, 48 Our rst attempt here to show protection from viral transmission a er exposure met with mixed success. However, two of four mice that were treated within 4 hours of exposure did not become infected and all the treated mice had less severe signs of infection as measured by T cell counts and plasma viremia.
ese data suggest that interfering with viral gene expression a er infection may be e ective in vivo.
Improvements in the design of CD4-AsiCs or altered dosing likely can enhance protection from delayed challenge and postexposure prophylaxis. In these experiments, we used the same doses as in our previous study, 40-80 pmol/mouse/injection, which translates to <0.2 mg/kg/mouse. Although these doses are practical, improved design might reduce the dose, and hence, the cost of the microbicide, which is an important consideration for global use. e CD4-AsiCs, which are our rst design, could be optimized for more e cient uptake into cells or escape from endosomes (the bottlenecks in intracellular delivery), stability within cells (the t 1/2 in serum or genital uid is already >3 days 14, 28, 30 and doesn't need improvement), or e ciency of incorporation into the RNA-induced silencing complex or target gene interference. is might be accomplished by optimizing the aptamer sequence, the linker between the aptamer and the siRNA 49 or choice of siRNA sequence, altering the chemical modi cations of the RNA bases (here only the long strand was modi ed with 2′-uoropyrimidines), 30 or attaching small molecules to enhance cellular uptake or endosomal escape. Drug optimization will likely not only enhance protection, but might also reduce the drug concentration and cost needed for e ective prevention.
MATERIALS AND METHODS
CD4-AsiC synthesis. CD4-AsiCs were synthesized by in vitro transcription and puri ed as previously described. 14, 28, 30 Flow cytometry. Direct immunostaining of CD3, CD4, CD8, CD14, CD45, and CCR5 was performed using 1/20 dilutions (1/5 dilution for CCR5) of uorescently conjugated murine mAb for 30-60 minutes at 4 °C (BioLegend, San Diego, CA). Cells were stained in PBS containing 0.5% FCS, 1 mmol/l EDTA, and 25 mmol/l HEPES. Samples were washed twice in the same bu er. Data for samples in one and two-color experiments were acquired using the FACSCalibur (BD Biosciences, Franklin Lakes, NJ), whereas in multi-color experiments, they were acquired using the FACS-Aria II (BD Biosciences). All data analysis was performed using FlowJo (Treestar, Ashland, OR).
Viruses. HIV BaL virus, which was used to infect cervicovaginal explants, was obtained from the NIH AIDS Research and Reference Reagent Program (NIH-ARRRP). Viral stocks were generated by infecting pooled PBMCs that had been stimulated with phytohemagglutinin (4 µg/ml) in RPMI supplemented with 10% fetal bovine serum (H10) + 60 IU/ml rIL-2 (Chiron, Charlotte, NC). HIV-1 JR-CSF viral stocks, which were used to infect BLT mice, were produced through transfection of HEK293 cells as described.
14 Supernatant virus was concentrated 1:50 using the PEG-it Virus Precipitation Solution (System Biosciences, Mountain View, CA) as per the manufacturer's protocol. p24 Ag levels in culture supernatants were measured by HIV-1 p24 Ag enzyme-linked immunosorbent assay (ELISA) kit (Perkin Elmer, Waltham, MA).
BLT mice. All in vivo experiments were performed using NOD/ SCID/IL2Rγ −/− (NSG) mice, bearing humanized bone marrow following reconstitution with CD34 + cells from human fetal liver, and surgical human thymic gra ("BLT mice"), prepared as previously described.
14,31 Uniformity of HIV infection in HIV challenge experiments was obtained by requiring high levels of human immune reconstitution. Criteria for BLT reconstitution were >25% of peripheral blood cells within a lymphocyte gate on forwardversus-side scatter plots; >50% of cells in the lymphocyte gate are human (hCD45 + /mCD45 − ); and >40% of human cells in the lymphocyte gate are T cells (hCD3 + ). Approximately 1 week before use, mice were treated with 2 mg medroxyprogesterone subcutaneously (Besse, New York, NY). Equal numbers of mice generated from a single fetal donor were assigned to each experimental group. In some experiments, all mice were from 1 donor; in others, mice from two or three donors were used. In some experiments, some of the experimental mice died from a transplantation-related wasting syndrome during the course of the experiment. ese deaths occurred equally in HIV-infected and -uninfected groups and were not related to viral load or CD4 counts or treatment, and thus were thought to be unrelated to either HIV infection or treatment. Animal work was approved by the Animal Care and Use Committees of Massachusetts General Hospital, University of Massachusetts Medical School, and Harvard Medical School.
HIV-1 infection.
For HIV infection of BLT mice, HIV JR-CSF (10 5 TCID 50 ) diluted in PBS to a 10 μl nal volume was applied atraumatically to the vaginal mucosa using 10 μl XL pipette tips (Neptune Scienti c, San Diego, CA). Using this challenge dose, all control mice became infected.
Vaginal stability assay. CCR5 CD4-AsiC (2 nmol) synthesized using 2′-uoro-pyrimidines suspended in either 100 μl PBS or HEC gel were added to 100 μl of vaginal uid obtained from a healthy preovulatory donor. At regular intervals, 20 μl was removed, resuspended in gel loading bu er, and frozen at −80°C before resolution by PAGE analysis. RNA content was analyzed by ethidium bromide staining and densitometry, and amounts were calculated relative to RNA content at time 0.
Human cervical polarized tissue explants. Human cervical tissue was obtained from healthy donors undergoing hysterectomy for benign conditions. Tissue was immediately sectioned into ~3 mm 3 specimens and then oriented on the membrane of a 12-transwell system (Corning, Tewksbury, MA) with the apical epithelial surface facing up. Explants were then embedded in 3% agarose as described 14, [28] [29] [30] and the integrity of the agarose seal was tested using Trypan blue. e polarized explants were cultured in 200 μl H10 medium. Cy3-labeled AsiCs, in 50 μl Optimem (Invitrogen), were applied to the apical surface, and the explants were then incubated at 37 °C for 4-6 hours before adding 150 μl H10 to each well. e treatment was repeated 24 hours later and then the tissue was incubated for an additional 48 hours at 37 °C before collagenase digestion and analysis. Tissues were obtained in accordance with institutional regulations concerning human samples.
Collagenase digestion of vaginal tissue. For experiments to assess gene silencing in explants, specimens were removed from the transwell 48 hours a er the second application of RNA. Ten polarized explants per treatment condition were pooled and digested in 10 ml RPMI containing 1 mg/ml collagenase II (Sigma) for 30 minutes at 37°C with shaking. Samples were disrupted in a gentleMACS dissociator (Miltenyi, Auburn, CA) using the C.01 program for 30 minutes at 37 °C both before and a er collagenase digestion. Cell suspensions were passed through a 70 µm cell strainer (BD Falcon, Franklin Lakes, NJ), washed with 30 ml RPMI and then stained for ow cytometry analysis. e same procedure was followed for vaginal tissue dissected from individual BLT mice.
In vivo treatment and HIV protection. Xylazine/Ketamine anesthetized mice were treated with CD4-AsiCs by atraumatic application to the vaginal mucosa of PBS or HEC solution in 15 μl according to the indicated schedule. Mice were kept supine for 5 minutes a er each application. e HEC gel formulation was prepared by mixing the HEC gel (NIH-ARRRP) in a 1:1 ratio with sterile PBS. For AsiC preparations, RNAs were added to the diluted mixture, vortexed, and applied IVAG according to the experimental protocol. Mice were sacri ced at times indicated for each experiment. HIV protection was assessed in NSG-BLT mice, treated IVAG with the speci ed concentrations of CD4-AsiCs or PBS (mock controls) in a 15 µl volume, that was divided into two 7.5 µl applications administered atraumatically using 10 µl XL pipette tips (Neptune).
Analysis of HIV infection.
Blood was obtained by venipuncture of the facial vein at weekly intervals for 8-10 weeks following HIV challenge. Cells were pelleted by centrifugation and plasma was stored at −80 °C until analysis. Cell pellets were twice treated with RBC lysis bu er (Sigma), washed with ow cytometry bu er described above and stained using a 1/20 dilution of CD3, CD4, and CD8 mAb. Viral RNA was extracted from 75 µl of plasma using Trizol (Invitrogen) according to the manufacturer's instructions. cDNA was reverse transcribed using SuperscriptIII (Invitrogen) and HIV-gag-speci c primers 37 according to the manufacturer's protocol. qRT-PCR was performed as above. e remaining serum was aliquoted for p24 Ag ELISA (Perkin Elmer) performed as per the manufacturer's instructions.
Statistical analysis. Data for most experiments were analyzed by Student's t-test. All P values are for two-tailed signi cance tests. For analysis of data based on independent experiments using samples from multiple donors, one-way analysis of variance with Dunnett multiple comparison test was performed using GraphPad Prizm (GraphPad So ware, San Diego, CA). P values below 0.05 were considered signi cant. e limit of detection was calculated using the method of ref. 50 and is shown as the average of the calculated limit of detection for each individual assay.
